Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01848301 · ClinicalTrials.gov registry record · Phase 1
Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation
A Phase 1 study, sponsored by Gladwin, Mark, MD.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01848301: Clinical Trial Phase 1 study, sponsored by Gladwin, Mark, MD.
NCT01848301 is a Phase 1 study that was terminated before completion, run by Gladwin, Mark, MD. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01848301, a Phase 1 study, was terminated before completion, sponsored by Gladwin, Mark, MD.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Coronary allograft vasculopathy (CAV) is the leading cause of late graft failure and second leading cause of late mortality after heart transplantation. CAV has been associated with a variety of traditional risk factors for atherosclerosis; however, immune mediated injury from development of de-novo donor-specific antibodies after transplantation also likely plays an important role. Similar to the progression of traditional atherosclerosis, it is likely that endothelial dysfunction is the precursor to the development of intimal thickening and CAV. The investigators hypothesize that coronary allograft vasculopathy after heart transplantation as defined by progressive neointimal hyperplasia is preceded by endothelial dysfunction, which in turn is at least partly mediated by donor specific antibodies. The investigators are proposing a prospective study in humans to test the above hypothesis and further mechanistically understand how CAV progresses. In this study the investigators will test for coronary endothelial function by infusing acetylcholine into the coronary artery and measure intimal hyperplasia by optical coherence tomography (OCT) and compare findings in patients with and without donor specific antibodies.
Interventions
- DRUG Acetylcholine
- DEVICE Optical Coherence Tomography
- PROCEDURE Brachial Artery Flow Mediated Dilation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-09 |
| Est. Completion | 2017-05-01 |
| Phase | Phase 1 |
Why NCT01848301 stopped before completion
NCT01848301 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 3 interventions - of which Acetylcholine is the first listed.
NCT01848301 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01848301 about?
NCT01848301 is a clinical study titled "Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation". Coronary allograft vasculopathy (CAV) is the leading cause of late graft failure and second leading cause of late mortality after heart transplantation. CAV has been associated with a variety of traditional risk factors for atherosclerosis; however, immune mediated injury from development of de-novo...
What is the current status of trial NCT01848301?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2012-09. Estimated completion is 2017-05-01.
What interventions are being tested in trial NCT01848301?
The interventions under investigation include: Acetylcholine (DRUG), Optical Coherence Tomography (DEVICE), Brachial Artery Flow Mediated Dilation (PROCEDURE).
Who is sponsoring clinical trial NCT01848301?
This trial is sponsored by Gladwin, Mark, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01848301's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia